
美国食品药品监督管理局(FDA)已批准 Sunharbo(通用名:asundexian,阿苏德西安)用于降低部分成年人复发卒中的风险。
The FDA has approved Sunharbo (asundexian) to reduce the risks of a recurring stroke in some adults.
该药物每日服用一片 50 毫克药片,并配合标准的抗血栓药物(如阿司匹林)一起使用。
The medication is taken as one 50-mg pill each day, along with standard blood-clot-preventing medicine, such as aspirin.
根据 FDA 发布的消息,该药旨在降低最近因血栓(非心源性血栓)导致卒中,或发生小卒中(短暂性脑缺血发作,即 TIA,指大脑供血暂时中断)的成年人再次发生卒中的风险。
It is designed to lower the risk of another stroke in adults who recently had a stroke caused by a blood clot (not a heart-related clot) or a mini-stroke (transient ischemic attack, or TIA), which is a temporary interruption of blood flow to the brain, according to the FDA release.
Sunharbo 是同类药物中首个能够阻断血液中特定蛋白(XIa 因子)的药物,该蛋白有助于血栓形成。
Sunharbo is the first medication of its kind to block a specific protein in the blood (factor XIa) that helps blood clots form.
印第安纳大学医学院心脏病专家、美国心脏病学会首席医疗官 Richard Kovacs 博士对 Fox News Digital 表示:“这阻断了凝血级联反应中一个非常特定的蛋白。”
"This blocks a very specific protein that’s part of the cascade of blood clotting," Dr. Richard Kovacs, a cardiologist at Indiana University School of Medicine and chief medical officer of the American College of Cardiology, told Fox News Digital.
批准基于一项涉及 37 个国家、12,327 名患者的 3 期随机试验,所有患者均近期发生过非心源性缺血性卒中或高风险 TIA。
Approval followed a phase 3 randomized trial involving 12,327 patients across 37 countries, all of whom had a recent non-cardioembolic ischemic stroke or high-risk TIA.
在每日口服一次 50 毫克阿苏德西安并配合抗血小板治疗、为期 14.2 个月的患者中,与服用安慰剂并配合抗血小板治疗的对照组相比,缺血性卒中发生率相对降低了 26%。
Among those who took 50 mg of asundexian orally once daily plus antiplatelet therapy for a period of 14.2 months, there was a 26% relative reduction in ischemic stroke compared to groups who took a placebo along with antiplatelet therapy.
尽管总体重大出血风险未显著增加,但在某些亚组中该副作用风险较高。不过,服用阿苏德西安的患者胃肠道出血更常见,且 75 岁以上患者在前 90 天内重大出血风险增加。
Although there was not a significant overall increase in major bleeding, the risk of that side effect was higher in certain subgroups. However, gastrointestinal bleeding was more common with asundexian, and major bleeding was increased among patients older than 75 during the first 90 days.
服用阿苏德西安的患者发生卒中、心脏病发作或死亡的风险也低于接受安慰剂的患者。
Patients who took asundexian also had a lower risk of stroke, heart attack or death compared with those who received a placebo.
服用阿苏德西安的患者中约 6.6% 发生卒中,而安慰剂组为 8.8%。
About 6.6% of patients taking asundexian experienced a stroke, compared with 8.8% in the placebo group.
Kovacs 表示:“所以它并不能完全消除二次卒中的风险。”
"So it doesn’t completely eliminate the risk of a second stroke," Kovacs said.

对比 11.1%)。
The risk of death from heart-related causes, heart attack or stroke was also lower among patients taking asundexian (9.2% versus 11.1%). Similarly, 10.5% of patients taking the medication experienced death from any cause, compared with 12.3% of those receiving a placebo.
同样,服用该药物的患者因任何原因死亡的比例为 10.5%,而接受安慰剂的患者为 12.3%。研究结果于 11 月 9 日发表在《新英格兰医学杂志》上。这项由阿苏德西安制造商拜耳资助的试验存在若干局限性。
The findings were published in The New England Journal of Medicine on Nov. 9. The trial, which was funded by Bayer, the manufacturer of asundexian, had several limitations.
由于患者平均接受治疗约 14 个月,该药物的长期安全性和有效性尚不清楚。该研究还排除了患有某些心脏疾病的患者以及中风更严重的患者。
Because patients were treated for an average of about 14 months, long-term safety and effectiveness of the medication are unclear. The study also excluded patients with certain heart conditions and those with more severe strokes.
科瓦克斯表示:“重要的是,这种药物不适用于因心房颤动或心脏瓣膜问题导致中风的患者。”
"Importantly, this drug is not for patients who have had strokes due to atrial fibrillation or due to a valve problem in their heart," Kovacs said.

研究人员指出,需要更长期的研究,以确定老年患者、代表性不足人群以及中风程度更严重患者的安全性和有效性。科瓦克斯强调,患者应在中风后尽快与医疗团队讨论该药物。
Longer-term studies are needed to identify safety and effectiveness among older patients, underrepresented populations and patients with greater stroke severity, the researchers noted. Kovacs emphasized that patients should discuss the medication with their care team soon after a stroke.
他说:“在批准该药物的临床试验中,该药物是在中风后非常早的时候给予的——在 72 小时内。因此,尽早进行关于这种药物是否适合患者的讨论非常重要,通常是在住院期间。”这位心脏病专家强调,药物只是预防再次中风的一个方面。
"In the clinical trial that approved this drug, this drug was given very soon after the stroke – within 72 hours," he said. "So it’s important to have that conversation about whether this is a drug for the patient early on, often in the hospital." Medication is only one part of preventing another stroke, the cardiologist emphasized.

“这些患者中许多人的中风原因是动脉粥样硬化,”他说,并将这种状况描述为“斑块堆积,可能导致循环问题和大脑供血不足。”
"The cause of the stroke in many of these patients was atherosclerosis," he said, describing the condition as "plaque buildup that can cause circulation problems and the lack of blood flow to the brain."
“所以,对于任何中风患者来说,除了服用这种药物外,做所有其他能做的事情来预防二次中风都很重要——比如戒烟、保持胆固醇低水平、健康饮食,最重要的是锻炼身体。”
CLICK HERE TO "So it’s important for any stroke patient to do all the other things that you can do in addition to this medicine to prevent a second stroke – like stopping smoking, keeping your cholesterol low, eating healthy, and most importantly, getting exercise."
根据美国疾病控制与预防中心(CDC)的数据,美国每年有超过79.5万人中风,其中约18.5万人曾经中风过。大约四分之一的中风幸存者会在五年内再次中风。
More than 795,000 people in the U.S. have a stroke each year, including about 185,000 who have had one before, according to the CDC. About one in four stroke survivors experiences another within five years.